Sernova (TSE:SVA) has released an update.
Sernova Corp., a clinical-stage biotech company, has announced an oversubscribed private placement offering, receiving $4.7M in binding agreements against its offer of $4M. The investment, which is subject to TSX approval, indicates strong investor confidence in the company’s innovative Cell Pouch System platform aimed at treating chronic diseases like diabetes and thyroid disease.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
